CA3086883A1 - Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif - Google Patents

Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif Download PDF

Info

Publication number: CA3086883A1
Authority: CA; Canada
Prior art keywords: gold nanoparticle; coronavirus; present; composition; gold
Prior art date: 2020-07-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA3086883A

Other languages

English (en)

Inventor

Chur Chin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-07-14

Filing date

2020-07-14

Publication date

2022-01-14

2020-07-14 Application filed by Individual filed Critical Individual

2020-07-14 Priority to CA3086883A priority Critical patent/CA3086883A1/fr

2022-01-14 Publication of CA3086883A1 publication Critical patent/CA3086883A1/fr

Status Abandoned legal-status Critical Current

Links

PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 46
239000010931 gold Substances 0.000 title claims abstract description 42
229910052737 gold Inorganic materials 0.000 title claims abstract description 42
239000002105 nanoparticle Substances 0.000 title claims abstract description 41
208000025721 COVID-19 Diseases 0.000 title claims abstract description 19
239000000203 mixture Substances 0.000 title claims description 21
239000004480 active ingredient Substances 0.000 title claims description 8
108700010904 coronavirus proteins Proteins 0.000 claims abstract description 13
230000004660 morphological change Effects 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims description 12
239000003112 inhibitor Substances 0.000 claims description 8
230000017854 proteolysis Effects 0.000 claims description 8
ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 claims description 5
239000007922 nasal spray Substances 0.000 claims description 2
229940097496 nasal spray Drugs 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 abstract description 12
208000001528 Coronaviridae Infections Diseases 0.000 abstract description 6
230000002265 prevention Effects 0.000 abstract description 3
241000711573 Coronaviridae Species 0.000 description 16
210000004027 cell Anatomy 0.000 description 11
101710198474 Spike protein Proteins 0.000 description 8
229940096437 Protein S Drugs 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000003814 drug Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
241000700605 Viruses Species 0.000 description 5
229940079593 drug Drugs 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
101710114810 Glycoprotein Proteins 0.000 description 3
101710167605 Spike glycoprotein Proteins 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 2
229960000772 camostat Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000029142 excretion Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000007501 viral attachment Effects 0.000 description 2
230000007502 viral entry Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000000592 Artificial Cell Substances 0.000 description 1
241001678559 COVID-19 virus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000003633 blood substitute Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000026502 entry into host cell Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
-1 generally Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA3086883A 2020-07-14 2020-07-14 Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif Abandoned CA3086883A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA3086883A CA3086883A1 (fr)	2020-07-14	2020-07-14	Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA3086883A CA3086883A1 (fr)	2020-07-14	2020-07-14	Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif

Publications (1)

Publication Number	Publication Date
CA3086883A1 true CA3086883A1 (fr)	2022-01-14

Family

ID=79296081

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3086883A Abandoned CA3086883A1 (fr)	2020-07-14	2020-07-14	Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif

Country Status (1)

Country	Link
CA (1)	CA3086883A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2022170845A1 (fr) *	2021-02-10	2022-08-18	深圳先进技术研究院	Utilisation d'un nanomatériau d'or pour inhiber le coronavirus
CN116047066A (zh) *	2022-07-19	2023-05-02	广州国家实验室	Sgk1作为靶点在制备诊断、预防、治疗冠状病毒所致疾病的产品中的应用

2020
- 2020-07-14 CA CA3086883A patent/CA3086883A1/fr not_active Abandoned

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2022170845A1 (fr) *	2021-02-10	2022-08-18	深圳先进技术研究院	Utilisation d'un nanomatériau d'or pour inhiber le coronavirus
CN116047066A (zh) *	2022-07-19	2023-05-02	广州国家实验室	Sgk1作为靶点在制备诊断、预防、治疗冠状病毒所致疾病的产品中的应用
CN116047066B (zh) *	2022-07-19	2024-02-20	广州国家实验室	Sgk1作为靶点在制备诊断、预防、治疗冠状病毒所致疾病的产品中的应用

Publication	Publication Date	Title
CN114786659B (zh)	2025-02-14	用于治疗汉坦病毒感染的mek抑制剂
JP2505944B2 (ja)	1996-06-12	（Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
US20180235934A1 (en)	2018-08-23	Noradrenergic drug treatment of obstructive sleep apnea
CA3086883A1 (fr)	2022-01-14	Composition pour prevenir ou traiter la covid-19 comprenant une nanoparticule d'or comme ingredient actif
JP2014501718A (ja)	2014-01-23	ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
US20210308180A1 (en)	2021-10-07	Composition for preventing or treating covid-19, including gold nanoparticle as active ingredient
JP2025004215A (ja)	2025-01-14	抗不整脈製剤
KR20010032009A (ko)	2001-04-16	수면성 무호흡의 치료에 미타자핀을 사용하는 방법
WO2008151092A1 (fr)	2008-12-11	Procédés et compositions concernant l'administration d'oxybutynine
WO2021195521A1 (fr)	2021-09-30	Méthodes de traitement d'infections à coronavirus
AU2020205258A1 (en)	2022-02-03	Composition for preventing or treating COVID-19, including gold nanoparticle as active ingredient
KR102875179B1 (ko)	2025-10-23	폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
JP2011144111A (ja)	2011-07-28	軸性近視の予防または治療剤
KR20230018474A (ko)	2023-02-07	급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
JP5828007B2 (ja)	2015-12-02	局所投与型の嚥下障害改善用医薬品
EA025224B1 (ru)	2016-12-30	ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ
JP2005513105A (ja)	2005-05-12	臨床的うつ病を治療するためのデオキシペガニンの使用
US20220016160A1 (en)	2022-01-20	Method for preventing or treating infection of respiratory virus utilizing gold nanoparticles
CN114585364B (zh)	2025-09-02	谷氨酸2b受体拮抗剂和σ受体激动剂作为止咳药的用途
JP2006522044A (ja)	2006-09-28	偏頭痛の治療のための化合物１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］−カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンの塩酸塩とスマトリプタンとの組み合せ使用
WO1997044062A1 (fr)	1997-11-27	Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires
CN1897952B (zh)	2010-12-08	中性白细胞增多抑制剂
JPWO2019197406A5 (fr)	2022-04-18
WO2022270656A1 (fr)	2022-12-29	Composition pour la prévention ou le traitement d'une infection par le virus nipah comprenant des nanoparticules d'or en tant que principe actif
JP6024006B2 (ja)	2016-11-09	Ｈｔｌｖ−ｉ関連脊髄症の予防または治療剤

Legal Events

Date	Code	Title	Description
2024-03-12	FZDE	Discontinued	Effective date: 20240116